UBS Group
KRYS icon

UBS Group’s Krystal Biotech KRYS Stock Holding History

UBS Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.16M Buy
+16,100
New +$4.28M ﹤0.01% 4261
2025
Q4 		– Sell
-148,500
Closed -$26.2M – 10886
2025
Q3 		$26.2M Buy
148,500
+96,300
+184% +$14.4M ﹤0.01% 2267
2025
Q2 		$7.18M Buy
+52,200
New +$7.67M ﹤0.01% 3482

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's KRYS Position: Q1 2026 in Review

UBS Group reduced its Krystal Biotech (KRYS) stake by 10% in Q1 2026, selling an estimated $4.28M and leaving 143,525 shares worth $37.1M. The position accounts for 0.01% of the portfolio, ranked #1940.

UBS Group first reported a position in KRYS in Q3 2017 and has held it in 29 quarters since. The position peaked at $39.3M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • UBS Group held 143,525 shares of Krystal Biotech worth $37.1M as of Q1 2026.
  • UBS Group sold 16,070 Krystal Biotech shares in Q1 2026, an estimated $4.28M.
  • Krystal Biotech made up 0.01% of UBS Group's portfolio in Q1 2026, its #1940 holding.
  • UBS Group first reported a position in Krystal Biotech in Q3 2017 and has held it in 29 quarters since.
  • UBS Group's Krystal Biotech position peaked at $39.3M in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.